Taysha Gene Therapies Inc. (TSHA) at a glance
Taysha Gene Therapies Inc. (TSHA) is a small-cap Healthcare company. It trades at $5.77, with a P/E of 2.5, a 0% profit margin and revenue decline of 100%. It does not pay a dividend. Vestovix scores it 48/100 overall. Its strongest dimension is Value (92/100) and its weakest is Growth (11/100). Its volatility is roughly in line with the market.
- Price
- $5.77
- Market cap
- $1.88B
- P/E ratio
- 2.5
- Dividend yield
- None
- Beta
- 1.19
- 52-week range
- $2.71 to $7.30
Value
92
Growth
11
Income
40
Safety
38
Momentum
62
Other Healthcare stocks
See allDHR.PR.A50
Danaher Corp
$1,841.01+0.00%
2.58% yield
LLY68
Eli Lilly and Company
$1,170.12-0.96%
0.57% yield
JNJ61
Johnson & Johnson
$268.94+0.73%
2.18% yield
ABBV46
AbbVie Inc.
$265.10-0.86%
2.96% yield
UNH56
UnitedHealth Group Incorporated
$373.29-0.34%
2.16% yield
MRK60
Merck & Co., Inc.
$150.95-0.98%
2.79% yield
ABT54
Abbott Laboratories
$103.69+0.92%
2.16% yield
AMGN65
Amgen Inc.
$410.34-1.05%
2.76% yield